

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

THIS PAGE BLANK (USPTO)

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01N 1/28, 25/48, 33/48, 35/04	A1	(11) International Publication Number: WO 95/05590 (43) International Publication Date: 23 February 1995 (23.02.95)
(21) International Application Number: PCT/US94/09226 (22) International Filing Date: 16 August 1994 (16.08.94) (30) Priority Data: 08/107,381 16 August 1993 (16.08.93) US (60) Parent Application or Grant (63) Related by Continuation US 08/107,381 (CIP) Filed on 16 August 1993 (16.08.93) (71) Applicant (for all designated States except US): AKZO NOBEL N.V. [NL/NL]; P.O. Box 186, Velperweg 76, NL-6800 LS Arnhem (NL). (72) Inventors; and (75) Inventors/Applicants (for US only): FISCHER, Timothy, J. [US/US]; 6405 Pernod Way, Raleigh, NC 27613 (US). CALLAHAN, Janet, B. [US/US]; 216 Cobblestone Drive, Chapel Hill, NC 27516 (US). BRAUN, Paul, J. [US/US]; 612 Kingsbury Drive, Durham, NC 27712 (US). GIVENS, Thomas, B. [US/US]; 3522 Red Mountain Road, Rougemont, 27572 (US). HULETTE, William, C. [US/US]; 1804 US 70E, Hillsborough, NC 27278 (US). HOFFMAN, Julie,	F. [US/US]; 3332 Oak Drive, Ypsi, MI 48197 (US). LINK, John, G. [US/US]; 4819 Northbury Circle, Durham, NC 27712 (US). SWOPE, Charles, H. [US/US]; 5021 Wood Valley Drive, Raleigh, NC 27613 (US). (74) Agents: BLACKSTONE, William, M. et al.; Akzo Nobel N.V., 1330 Piccard Drive, Rockville, MD 20850 (US). (81) Designated States: AU, CA, FI, JP, KR, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: METHOD AND INSTRUMENT FOR AUTOMATICALLY PERFORMING ANALYSIS RELATING TO THROMBOSIS AND HEMOSTASIS		
(57) Abstract <p>This invention relates to a novel, fully automated spectrophotometric analyzer and method used for testing blood samples in the clinical laboratory for thrombosis and hemostasis properties. The analyzer tests samples in a fully randomized format, and is fully automated in the areas of specimen handling, sample preparation, optical inspection, data analysis and total quality control for imprecision and bias.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

METHOD AND INSTRUMENT FOR AUTOMATICALLY PERFORMING
ANALYSIS RELATING TO THROMBOSIS AND HEMOSTASIS

This application is related to the following
copending U.S. Patent Applications and issued patents,
which are owned by the Assignee of the present
Application, and the disclosures of all but No. 6 are
5 incorporated herein by reference:

(1) Serial No. 07/443,952, to Swope et al.,
titled "Multichannel Optical Monitoring Systems", now
U.S. Patent 5,002,392;

10 (2) Serial No. 07/443,956, to Karp et al.,
titled "Cuvette and Linear Drive Mechanism Therefor",
now U.S. Patent 5,040,894; and

(3) Serial No. 07/443,954, to Hoffman et al.,
titled "Apparatus and Method for Cleaning Reagent
15 Delivery Probes", now U.S. Patent 4,989,623.

(4) Serial No. 07/443,784, to Karp et al.,
titled, "Cuvette", now U.S. Patent Des. 325,090.

(5) Serial No. 07/674,957, to Keiter et al.,
titled, "Heated Liquid Sampling Probe for an Automated
20 Sampling Apparatus," now U.S. Patent 5,178,019.

(6) Serial No. 07/916,712, to Lewis et al.,
titled, "Cassette and Cuvette Loading Mechanism".

(7) Serial No. 07/896,579, to Haugen, titled,
"Method for Scanning Photodiodes".

25 (8) Serial No. 07/443,953, to Driscoll,
titled, "Method of Monitoring Reagent Delivery in a
Scanning Spectrophotometer," now U.S. Patent 5,068,181.

-2-

(9) Serial No. 07/833,950, to Fischer et al.,
titled, "Method and Instrument for Automatically Per-
forming Analysis Relating to Thrombosis and Hemostasis."

5 (10) Serial No. 07/443,951, to Fischer et al.,
titled, "Method and Instrument for Automatically Per-
forming Analysis Relating to Thrombosis and Hemostasis."

This invention relates to a novel, fully automated
spectrophotometric analyzer and the method used for
assaying for thrombosis and hemostasis properties of
10 blood samples. The analyzer tests samples in a fully
randomized format, and is fully automated in the areas
of specimen handling, sample preparation, optical
inspection, signal processing and quality
assurance/control for imprecision and bias allowing for
15 numerous assays to be performed on a single sample. The
assays vary considerably in nature and fall into three
categories: clot based, chromogenic, and immunological.
No single automated methodology or instrumentation
currently exists that successfully performs all of these
20 types of assays concurrently.

BACKGROUND OF THE INVENTION

Thrombosis and hemostasis testing is the in vitro
study of the ability of the blood to form clots and to
25 break clots in vivo. As thrombotic and hemostasis
pathways form a part of very important disease states
ranging from hemophilia to strokes and heart attacks,

-3-

the testing of a patients capabilities in thrombosis and hemostasis is a critical diagnostic tool. Should a patients ability to form clots in vitro fall outside of the established norm, or should certain markers be out of the normal range, the serum or plasma sample is further assayed to determine the reason for the problem. These assays are in standard use in all hospital laboratories.

Coagulation assays began, and are still done in many instances, in a test tube using hand methods. Early on, the goal was to determine if a patients blood sample would clot after certain materials were added. It was later determined that the amount of time it took for the sample to clot was related to congenital or acquired disorders. This type of testing is extremely dependent on the laboratory technologist, and so, some form of standardization was seen to be needed. As technology improved and stronger correlations between in vivo conditions and in vitro assays were established, semi-automatic coagulation analyzers began to appear.

These coagulation analyzers primary usefulness is to remove the subjectiveness in determining the exact second a clot forms in a sample in vitro. However, these analyzers did and do not have the automation required to remove variability associated with sample preparation. Furthermore, advances in clinical thrombosis and hemostasis assays resulted in the

-4-

development of new types of assays that aided in the diagnosis and treatment of a patient and semi-automated coagulation analyzers seldom possess the ability to perform more than one assay at a time. This is because reagent pathways are dedicated to a single reagent, resulting in a limited number of assays that can be performed on each instrument. Generally, the semi-automated instrumentation performs one test in a batch mode, maintaining one profile of temperature vs. time for each different type of assay.

Semi-automated analyzers also require the technician to manually deliver the plasma sample. A new sampling device, generally a pipette tip, is used for each specimen to eliminate plasma cross-contamination between samples. Using a common sampling means for reagents and samples requires novel approaches to eliminate cross contamination of samples and reagents.

In order to have the next generation of analyzers, fully automated analyzers must be developed to be able to use the same sampling device for all specimens and to have common pathways for delivery of multiple reagents, and to provide a universal time and temperature profile compatible with a multitude of assays.

Additionally, any complex computations needed to be performed for an assay are done by an operator when semi-automated analyzers are used. Differences in operators techniques in analyzing data lead to increased

-5-

levels of inaccuracy of the data. Another feature needed to improve coagulation testing is improved and standardized data analysis techniques to obtain the desired performance characteristics from inter and intra laboratory comparisons, which would result in a higher standard of care for the patient.

Quality control and system monitoring of the semi-automated coagulation analyzers are primitive and inadequate when compared to the state of the art.

The next generation of analyzers, a fully automated thrombosis and hemostasis analyzer, requires a statistically controlled, on-line quality assurance program that monitors the system integrity, as the analysis are being performed. This program must not only identify failures after they have occurred, but predict potential failures before they occur.

Another area of the clinical laboratory, the clinical chemistry laboratory, has had fully automated analyzers for a number of years. The tests performed and the types of reactions read, including colorimetric, fluorescent and luminescent measurement, are substantially different and have endpoints that are easier to detect than do coagulation-based tests, those performed in the coagulation laboratory. The same progress towards full automation has not been seen in the coagulation laboratory as in the clinical chemistry laboratory.

-6-

In general, the basic tests or assays performed in the coagulation laboratory using plasma, serum or whole blood include performing the Partial Thromboplastin Time ("PTT"), the Prothrombin Time ("PT"), the Activated
5 Partial Thromboplastin Time ("APTT"), testing for deficiencies in Factors such as Factors II, V, VII, VIII, IX, XI, XII and others, and chromogenic and immunological testing for thrombosis or hemostasis markers. These, among others, have proven to be much
10 more difficult to do on automated equipment than have the clinical chemistry tests. This is because the tests run in the coagulation laboratory usually: (1) involve unique time/temperature profiles; (2) are extremely sensitive to both reagent and plasma carryover; (3)
15 require unique data analysis; and (4) have unique quality control requirements.

A method for automatically performing a variety of coagulation-related assays and a fully automated coagulation analyzer is needed to perform a host of
20 assays in a totally random format that would expedite patient diagnosis. It must have the ability to control the sample preparation stages of an in vitro assay; to perform all thrombosis and hemostasis assays using a common temperature profile; to measure the reaction that
25 occurs when the appropriate materials are added; and to determine both the immediate response as well as to provide mathematical tools for calculating complex

-7-

results. This entire process should be monitored using an on-line quality control package that is designed to minimize imprecision associated with random error and to minimize bias associated with error due to the system itself, systemic error.

This type of fully automated coagulation analyzer would provide more accurate results that in turn would allow for quicker and more accurate diagnosis of current or predicted illness, thereby allowing for better treatment of the patient.

SUMMARY OF THE INVENTION

The present invention includes a method for automatically assaying for hemostasis and thrombosis parameters in a plasma, serum or whole blood sample comprising:

a) providing a programming input means for identifying the sample and scheduling one or more hemostasis and thrombosis-related assays to be performed on the sample;

b) providing a specimen handling means for automatically transferring an aliquot of the sample from a holding device to a test well in a cuvette;

c) providing a sample preparation means for automatically adding reagents needed for an assay to measure hemostasis or thrombosis parameters to the sample in the test well at a specified time and

-8-

temperature, accommodating a universal thermal profile, to obtain a reaction, wherein the order of the reagents added can be in a random access format thereby eliminating the need for batch analysis;

5 d) providing a detecting means for detecting the reaction in the well and measuring the data from the reaction;

 e) providing a processing means for mathematically processing the measured data to evaluate a change in or
10 magnitude of the measured data from the reaction in the well;

 f) providing a reporting means to report said results of the evaluation by the processing means; and

 g) simultaneously with all of steps a) - f) above,
15 providing a quality assurance means for monitoring the performance of the method and evaluating the validity of the reported data for the sample,

 thereby automatically performing hemostasis and thrombosis-related assays and determining and reporting
20 results on hemostasis and thrombosis parameters in the sample.

 The present invention also provides a fully automated coagulation analyzer that responds to all of the needs stated above. The linear, spectrophotometric
25 analyzer performs multiple hemostasis and thrombosis assays on samples of serum, plasma or whole blood in a totally random order. It is fully automated in terms of

-9-

specimen handling, sample preparation, optical inspection, signal processing, and total quality control for imprecision and bias. All hemostasis and thrombosis assays performed on the analyzer have been designed to share a common temperature profile, thereby allowing the random performance of assays. Each of these functions are also internally controlled through quality assurance programming. Each assay is defined by an assay definition file ("adf") allowing for flexibility in method definition. This flexibility is required in order to obtain the unique performance characteristics for each assay. Improvements in linearity, accuracy and the minimization of bias can be achieved by optimization of adf parameters.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 - The relative signal at various wavelengths is shown for two samples: a sample with mild Hemolysis, and a sample with Gross Hemolysis. Wavelengths of 515nm and 535nm are identified. The actual data collected is represented by data markers and these data markers are connected for each sample.

Figure 2 - The temperature of a sample is shown for a PT assay definition and an APTT assay definition as a function of time. Each sample/reagent delivery location is identified. The acceptable temperature ranges at

-10-

each instant in the temperature profile are identified by "zones."

Figure 3 shows the relative absorbance rates of a dye sample, serially diluted. A Least Squares regression line is also shown, and its goodness-of-fit measure r^2 .

Figure 4 shows the actual data points representing the clot times recovered for a serially diluted reference, and (1) the traditional curve and (2) the new curve fit through those points.

Figure 5 shows a smoothed signal, smoothed first derivative of that signal, and smoothed second derivative for data collected from a normal APTT assay. The location of the maximum of the second derivative (the clot time), is identified.

DETAILED DESCRIPTION OF THE INVENTION

The needs of the clinical coagulation laboratory for a fully automated coagulation analyzer have been met with this invention. Provided is an optical evaluation instrument and method that can handle a high throughput of patient samples with a high degree of versatility, adaptability and reliable automation. This is walk-away automation once patient samples still sealed in the original evacuated collection tube are loaded into the system.

-11-

The present invention includes a method for automatically assaying for hemostasis and thrombosis parameters as described above, in a plasma, serum or whole blood sample in a holding device, such as an evacuated collection tube, that can be stoppered. The assays may be performed in either a batch or random fashion, wherein the same assay or test is performed on all samples, multiple different assays are performed on each sample and a different assay is performed on each sample. This is accomplished by providing an integrated programming input means for identifying the sample and scheduling one or more hemostasis and thrombosis-related assays to be performed on the sample in any order. The programming means will accept and will allow the assays to be performed in a random format, i.e. in any order.

Next in the method is providing a specimen handling means for automatically transferring an aliquot of the sample from a holding device or a collection tube, with or without a stopper, to a test well in a cuvette. Because of various issues regarding the exposure of laboratory workers to blood borne contagious disease, being able to provide a specimen handling means to piece the septum or stopper without a human present is a definite asset in a clinical instrument or method.

Also, in the method is providing a sample preparation means for automatically adding the reagents needed for an assay to measure hemostasis or thrombosis

-12-

parameters to the sample in the test well at a specified time and temperature, accommodating a universal thermal profile, to obtain a reaction, and wherein the order of the reagents added can be in a random format eliminating the need for batch analysis. This methodology is needed because each assay or test performed in the coagulation laboratory is done with different time and temperature needs. The present method provides for a common universal thermal profile wherein each assay or test can be done within its particular parameters. The method provides for a heating and cooling track where each sample moves forward, but each at the speed needed for the assay to be performed, and the means for automatically adding the reagent needed at the proper temperature. Once the proper reagents are added at the proper time and temperature, the reaction begins.

Next, the method provides a detecting means for detecting the reaction in the well, and takes the result of said detection to mathematically compute data. This data, or the raw result of the assay or test, is provided a processing means wherein the computed data is evaluated to determine the change in or the magnitude of the reaction in the well, and when required, to transform the data into a diagnostically useful result.

Simultaneously with all of steps above, the method provides a quality assurance means for monitoring the performance of the method and evaluating the validity of

-13-

the reported data for the sample, thereby automatically performing hemostasis and thrombosis-related assays and determining and reporting results on hemostasis and thrombosis parameters in the sample.

5 A preferred way of performing the above described method of testing a large number of samples in a random order is done with the following instrument.

I. Overview of the Automated Analyzer

10 The analyzer is fully automated in terms of specimen handling, sample preparation, optical inspection, signal processing and total quality control for imprecision and bias, and a quality assurance program.

15

A. The Specimen Handling Segment.

The specimen handling segment of the analyzer is divided into four basic components consisting of positive patient identification of the sample, screening
20 for preanalytical variables, the ability to do closed container sampling and the ability to continuously supply cuvette wells for sample evaluation.

In greater detail, the specimen handling segment consists of:

25 1) a means for storing and continuously supplying a plurality of cuvettes to be used in the assays, each cuvette containing a plurality of reaction wells;

-14-

2) the optically readable code, such as a bar code or other coding, present on or incorporated into the sample collection tube or holding device containing a sample of serum, plasma or whole blood, is a patient identification and tracking device, and is also used in assay entry and automatic tracking of the assay during sample evaluation;

3) a means for the screening of and evaluating preanalytical variables prior to the beginning of any assay, such as hemolysis, bilirubin and lipemia; and

4) a sample insertion station including a means for automatically aspirating sample from the sample collection tube or holding device with or without a stopper and for automatically dispensing the aspirated sample into a reaction well of a cuvette.

B. The Sample Preparation Segment.

The sample preparation segment of the analyzer consists of four components: the means for defining unique reagent transferring sequences for each assay, random access ability, or the ability for a probe to aspirate reagent from a reagent container and dispense it into a predetermined cuvette well in any order and to aspirate and deliver different plasmas without cross contamination; the universal profile testing method; a means for performing auto dilutions of the sample; and a means for monitoring reagents and samples.

-15-

In greater detail, the sample preparation segment consists of:

1) an assay definition file ("adf") that allows for flexibility in how the reagents and plasmas are delivered. This flexibility is defined in terms of aspiration and dispense velocities, temperature, time out (delay) or timing sequences;

2) a reagent station, including a sample preparation means having the ability to randomly aspirate selected amounts of selected reagents from selected reagent containers as needed, and for dispensing the aspirated reagents into a reaction well of a cuvette according to the directions given in a programmed test for the sample in that reaction well. Each well of the cuvette may be programmed to have a different assay performed, and the reagent and sample in the reaction well forms a reaction volume which exhibits optical characteristics to be monitored by the analyzer;

3) a means for providing a universal temperature profile for the different assays programmed on the analyzer, which is an arrangement for temperature regulation of a fluid sample in a cuvette transported through various stations of the automated system for optically monitoring the sample in the cuvette, comprising: a means for transporting the cuvette through the various stations of the sample and reagent delivery system and optical monitoring system, the sample

-16-

temperature being controlled by the system; cooling means for cooling the sample in the first portion of the profile; heating means for heating the sample in the third portion of the profile in such a way as to maintain the sample temperature within base tolerance constraints; and a second section providing a means of providing a temperature ramp that defines the sample transition from the initial cool temperature to final warm temperature;

4) a means for automatically diluting samples, reference materials, and control materials through the use of programmed probes that perform a wide range of serial and nonserial dilutions; and

5) a temperature controlled housing for storing a plurality of reagent containers, each containing a respective reagent, and a plurality of sample collection tubes, each containing a fluid sample and presenting an optically readable code, such as a bar code or other equivalent coding, identifying the sample and a test to be performed on the sample. There is also a reagent tracking system that monitors the amount of available fluid in each discrete vial or container of reagent, present as a means for sensing liquid levels, one embodiment being a liquid-level sensor on each probe that aspirates and dispenses liquid.

-17-

C. The Optical Inspection Segment.

The optical inspection segment of the automated analyzer consists of three components, 1) a means for multiple wavelength analysis; 2) the use of a broad spectrum of wavelengths; and 3) continuous normalization of the fluctuations in light levels associated with sample to sample variability.

The optical inspection portion of the analyzer is provided for by:

1) and 2) a multichannel optical monitoring system as described in commonly owned US patent 5,002,392, issued on March 26, 1991, and incorporated herein by reference and commonly owned US patent application serial number 07/896,579, "Method for Scanning Photodiodes", also incorporated herein by reference; and

3) fluctuations in light levels associated with sample to sample variability, such as differences in color from sample to sample, are normalized through a quality assurance program prior to data analysis of the test results.

D. The Signal Processing Segment.

The signal processing segment of the analyzer consists of three components: the determination of kinetic endpoints; complex processing that determines endpoints other than clot formation, such as immunological complexes or chromogenic endpoints; and an

-18-

on-line database against which each test result can be compared.

In greater detail, the signal processing segment of the analyzer consists of:

5 1) a means for determining kinetic endpoints, for example, a computer program, that is able to determine the rate of acceleration that a clot is forming. This analysis is unique in that it is based on the kinetics of clot formation as opposed to the use of a threshold,
10 which is sensitive to biological, mechanical and electrical artifacts, thereby giving more accurate test results.

 2) a means for determining the endpoint of a variety of assays other than those based on clot
15 formation. For example, chromogenic assays such as ATIII and Protein C, and immunologic assays based on the interactions of antigens and antibodies, such as the assay for D-dimer, are read based on color changes or the presence or absence of agglutination or some type of
20 label; and

 3) a means for creating and storing reference curves that can be used for the evaluation of controls and patient samples.

Each of the above segments of the coagulation
25 analyzer is integrated with on-line quality control and

-19-

quality assurance programming. These are conducted to minimize bias and imprecision throughout the analyzer.

5 E. The Quality Assurance Segment.

 The satisfactory performance of any and all clinical laboratory assays depends on an effective quality control or quality assurance program, which controls each of the parameters listed below. Control
10 of these parameters minimizes imprecision associated with random error and minimizes bias associated with systemic error. The parameters controlled by the analyzer are:

- A) specimen integrity and handling;
- 15 B) reagent and expendable availability and quality;
- C) suitability and sensitivity of mechanical metering devices;
- D) suitability and sensitivity of reaction inspection and measuring devices;
- 20 E) suitability and sensitivity of data analysis methods, wherein statistical quality control rule analysis of the control data allows for the monitoring of the system in statistical control, assuring the validity of the results; and
- 25 F) minimized bias when compared to reference methods.

-20-

In order to assure accurate laboratory assay results, it has always been necessary to devise quality assurance methods to monitor important variables of each of the above critical parameters. This type of monitoring is equally necessary for manual, semi-automated and automated analytical methods. Prior to the present invention, skilled laboratory workers were responsible for monitoring these important variables for manual and semi-automated analytical methods using rudimentary off-line means. Some of these means included a traditional Levy Jennings approach to control ruling, visual inspection of samples for anomalies and no real-time monitoring of some instrument parameters was available. But the present invention requires on-line monitoring using sophisticated computer programming and integrated means.

Although each type of coagulation laboratory assay has specific critical parameters within the general parameters described above, some additional hemostasis and thrombosis assay critical parameters include:

- 1) Positive patient identification which includes bar code or similar identifier tracking, Delta check with previous specimen from the same patient; physiologic panic value evaluation; operational comments regarding the sample that follow data to the final report; and a statistical evaluation of replicate tests.

-21-

2) Preamanalytical Variables are variables that can contribute to an anomalous result. Examples are specimen age, plasma with clot contamination, the amount of anticoagulant present in the blood collection tube to plasma collected ratio, nonanalyte interferences, optimized thermal storage of specimens to offset degradation with activation, hemolysis of sample, bilirubin content, and lipemic samples.

3) Sampling from a primary specimen container that allows for repeated testing from the same closed container without plasma carryover effects or aerosolization of the blood samples.

4) Reagent and Expendable Availability - a broad diagnostic assay menu supported with the proper reagents, which are monitored, tracked and flagged for the operator when the levels are low; a liquid level sensor on the probe via, for example, capacitance touch facilities; flagging failure of the analyzer to dispense; logic programming omitting the performance of an assay if sufficient reagents not available; bar code or similar identifier identification of the actual placement of a reagent in reagent tray; and preloaded cuvette cassettes handling a large number of cuvettes insure the optical clarity of the cuvette by minimizing handling of cuvettes.

5) Reagent quality is insured by refrigerated storage; by a reagent tray cover that minimizes

-22-

evaporation and condensation; by the tracking of expiration dates; by tracking of reagent quality within each run, day-to-day, and month-to-month via an on-board quality control program using controls; by an assay specific quality control program which employs statistical rules with the ability to detect errors in the reagents; by tracking reagent quality independently of biological control plasmas using averaged patient data parameters; by normalizing minor drifts in reagent viability over time by assay calibration using calibrator plasmas; and by stirring reagents requiring stirring to maintain homogeneous suspension.

As can be seen from the above descriptions of the various segments of the automated coagulation analyzer, the segments are interdependent. Each of the four segments, specimen handling, sample preparation, optical inspection and signal processing are monitored and regulated and checked by on-board quality assurance and quality control program, providing an oversight function for all critical parameters. Each of these segments will be now more fully discussed along with the integration of these segments with the quality control and quality assurance features of the automated coagulation analyzer.

-23-

II. Specimen Handling

The present invention automatically handles the sample to be tested from the moment the collection tube containing the sample is placed in the analyzer. The analyzer has a first transporting device for transporting the sample collection tubes, in order, first to the programming station and then to the sample insertion station and a second transporting device for transporting the cuvettes through the sample insertion station, the reagent station and on to the optical monitoring device where the optical characteristics of the reaction volume in the respective reaction wells can be monitored.

According to a preferred embodiment of the invention, the sample collection tubes are evacuated and sealed by a septum, the tubes are sampled with a piercing/aspirating sample probe which deposits the proper amount of sample into the well of a cuvette. The preferred cuvette is described in Karp et al. US Des. 325,090 and US 5,040,894.

According to another aspect of the invention, the temperature controlled housing maintains the temperature of the evacuated collection tubes and the reagent containers between 9°C and 15°C.

Further, the second transporting device preferably includes a linear track for guiding the cuvettes and a drive mechanism for periodically moving the cuvettes

-24-

along the track in discrete increments. Preferably, the drive mechanism includes a lead screw and the cuvettes are each shaped for engaging the lead screw for being driven along the linear track in the manner described in the above referenced US 5,040,894. According to yet a further aspect of the invention, the cuvette storage includes a device for removing the cuvettes from the storage and placing the cuvettes onto the linear track.

Additionally, the first transporting device preferably includes a plurality of shuttles each for holding a plurality of sample collection tubes and means for moving the shuttles through the programming and sample insertion stations.

Each sample is given a machine-readable identification, such as a bar code, which is used in assay entry and during tracking of the assay. For example, a freshly drawn tube of blood is manually labelled with a bar code, and the bar code, patient identification and required tests are manually entered into the analyzer's computer. The tube is then placed into a shuttle and the shuttle placed in the shuttle storage area, where its bar code is automatically read by the analyzer and tracked by the quality control programming. The septum is pierced with the sampling probe, called Probe 1, which has been programmed as defined in the adf, to withdraw a specified amount of

-25-

sample from the tube or collection device, which proceeds to aspirate the sample and dispense it into a predetermined well of a predetermined cuvette. The probe is then washed in order to remove essentially all of the sample remaining on it, in order to avoid cross-contaminating the next sample. Wash solutions include, among others, water, bleach solutions, preferably a 10% bleach solution, or specifically formulated wash solutions that are capable of removing essentially all of the sample from the probe. At times later in the assay, each probe can be washed after each use, for the same reasons. However, another reason for washing a probe is because in these types of assays, should thrombin, thromboplastin or phospholipids contaminate the probe, they are extremely difficult to remove, and thereby contaminate the next assay well. Removal of these extremely sticky substances from the probe is needed for both the method and the instrument to perform.

The analyzer has been programmed so that this particular well will have a specific assay performed in it. The quality assurance program tracks the well at specified times throughout the test procedure, confirming assay identification, correct volume delivery, correct adf interpretation and proper temperature control at critical times.

-26-

Preanalytical variables, such as the presence of hemolysis, bilirubin, lipemia, and fibrin clots are determined in conjunction with the performance of an assay. This is accomplished by utilizing a bichromatic technique inspecting a baseline wavelength and wavelength where the substance of interest can be detected. Unique algorithms are then applied to quantitate each substance. For example, hemolysis is detected by monitoring transmittance at 535nm and 515nm and computing a hemolysis index, which is

$$\text{Hemolysis Index (HI)} = \frac{\text{Normalized transmittance at 535nm}}{\text{Normalized transmittance at 515nm}}$$

The heme unit of the hemoglobin molecule has adsorption at the 535nm band pass (see Figure 1).

Bilirubin is conducted the same way but uses 450nm and 710nm as the wavelengths of interest, while lipemia is measured by monitoring the normalized transmittance at 710nm.

III. Sample Preparation

The next step is the automatic preparation of the sample for testing. This includes the ability of the analyzer to access any reagent and to deposit it in a cuvette well; to wash the probe through which the reagent is accessed after each reagent is dispensed with

-27-

a wash solution as described above in order to avoid cross-contamination problems between reagents or reagents and samples; a universal profile testing method for all coagulation assays; a means for automatically
5 diluting the sample; and a means for monitoring levels of the reagents and samples in their cuvettes and tubes.

The random access movement of the probes is used to aspirate and dispense reagents and samples according to
10 test protocol for a particular assay (defined by the adf parameters), ordered or scheduled from the bar code of a given sample collection tube. This movement, and a description of the analyzers instrumentation, is more fully explained in the co-pending parent application,
15 USSN 07/833,950. Correct reagent/plasma volume delivery is monitored through the use of a novel dye tracking system, one type of which is described in U.S. patent number 5,068,181. The versatility provided by the presence of adf's allow the fully automated analyzer to
20 be optimized for each specific assay, allowing for the flexibility required for radically different assay formats.

Below are diagrams of adfs for three assays (Tables 1-3), Factor VIII reference curves, PT and plasminogen
25 reference curves. The first column notations A1, A2, A3 and A4 refer to the automated arms of the analyzer, the second column notations refer to various operations,

-28-

such as pumping velocity, dilution, and aspiration. The numbers after the colons are the editable parameters, dealing with each of the various operations, such as volume amount or number of dilutions or velocity. A number of 000 means that no function is performed by the particular arm at that particular point in time. The notations after A4 refer to the optical set-up of the analyzer.

-29-

TABLE 1 - adf Parameters for FVIII Ref. Curves

5	A1 Run Volume	: 50	A3 Reagent Volume	: 051
	A1 Pump Velocity	: 1000	A3 Reagent Airslug	: 040
	A1 Sample Location	: 001	A3 Pump Velocity	: 1250
	A1 Sampling Macro	: SFSTASP	A3 Reagent Location	: 001
	A1 Dilution Count	: 007	A3 Fetch Macro	: FETCH2
10	A1 Dilution Mix (1:x)	: 010	A3 Deliver Macro	: DELREAGENT
	A1 Dilution Sample	: 010	A3 Wash/Rinse Macro	: WASH
	A1 Dilution Primer	: 090	A3 Cleaner Volume	: 005
	A1 Dilution Aspirate	: 050	A3 Cleaner AirSlug	: 085
	A1 Dilution Macro	: SMIDASP	A3 Rinse Volume	: 800
15	A1 Non-Serial Dilution Count	: 000		
20	A1 Wash/Rinse Macro	: RINSEP	A4 Reagent Volume	: 051
	A1 Cleaner Volume	: 000	A4 Reagent AirSlug	: 040
	A1 Cleaner AirSlug	: 000	A4 Pump Velocity	: 1500
	A1 Rinse Volume	: 800	A4 Reagent Location	: 002
			A4 Fetch Macro	: FETCH2
25	A2 Dilution Volume	: 051	A4 Deliver Macro	: DELOPTICS
	A2 Primer Volume	: 000	A4 Wash/Rinse Macro	: WASH
	A2 Aspirate Volume	: 000	A4 Cleaner Volume	: 005
	A2 Dilution AirSlug	: 010	A4 Cleaner AirSlug	: 085
	A2 Pump Velocity	: 1000	A4 Rinse Volume	: 800
	A2 Buffer Location	: 005	Assay Blank time	: 007
30	A2 Dilution Macro	: FETCHOEL	Assay Maximum Time	: 240
	A2 Dilution Count	: 000	Normalization Value	: 3000
	A2 Dilution Concentrat	: 000	Replicate Count	: 000
	A2 Dilution Mix (1:x)	: 000	Wavelength Count	: 003
	A2 Non-Serial Dilution Count	: 000	5, 15, 20	
35				
40	A2 Throw Away Volume	: 000	Dltn Recalc Override:	: 0000
	A2 Middle Dilution	: 000	Spare 2	: 0000
	A2 Middle Primer Vol	: 000	Spare 3	: 0000
	A2 Middle Aspirate Vol	: 000	Spare 4	: 0000
	A2 Middle Dilution Macro:		Spare 5	: 0000
45	A2 Wash/Rinse Macro	: RINSEP		
	A2 Cleaner Volume	: 000	ADF Name	: FVIIIIR.ADF
	A2 Cleaner AirSlug	: 000		
	A2 Rinse Volume	: 800		

-30-

TABLE 2 - adf Parameters for PT

5	A1 Run Volume	: 51	A3 Reagent Volume	: 000
	A1 Pump Velocity	: 1000	A3 Reagent Airslug	: 000
	A1 Sample Location	: 001	A3 Pump Velocity	: 0000
	A1 Sampling Macro	: PIEREC	A3 Reagent Location	: 000
	A1 Dilution Count	: 000	A3 Fetch Macro	:
10	A1 Dilution Mix (1:x)	: 000	A3 Deliver Macro	:
	A1 Dilution Sample	: 000	A3 Wash/Rinse Macro	:
	A1 Dilution Primer	: 000	A3 Cleaner Volume	: 000
	A1 Dilution Aspirate	: 000	A3 Cleaner AirSlug	: 000
	A1 Dilution Macro	:	A3 Rinse Volume	: 000
15	A1 Non-Serial Dilution Count	: 000		
	A1 Wash/Rinse Macro	: RINSEP	A4 Reagent Volume	: 101
20	A1 Cleaner Volume	: 000	A4 Reagent AirSlug	: 040
	A1 Cleaner AirSlug	: 000	A4 Pump Velocity	: 1250
	A1 Rinse Volume	: 800	A4 Reagent Location	: 001
			A4 Fetch Macro	: FETCH3
	A2 Dilution Volume	: 000	A4 Deliver Macro	: DEOPTICS3
25	A2 Primer Volume	: 000	A4 Wash/Rinse Macro	: WASH1
	A2 Aspirate Volume	: 000	A4 Cleaner Volume	: 030
	A2 Dilution AirSlug	: 000	A4 Cleaner AirSlug	: 115
	A2 Pump Velocity	: 0000	A4 Rinse Volume	: 800
	A2 Buffer Location	: 000	Assay Blank time	: 005
30	A2 Dilution Macro	:	Assay Maximum Time	: 150
	A2 Dilution Count	: 000	Normalization Value	: 3000
	A2 Dilution Concentrat	: 000	Replicate Count	: 000
	A2 Dilution Mix (1:x)	: 000	Wavelength Count	: 003
	A2 Non-Serial Dilution Count	: 000	5, 15, 20	
35				
	A2 Throw Away Volume	: 000	Dltn Recalc Override	: 0000
40	A2 Middle Dilution	: 000	Spare 2	: 0000
	A2 Middle Primer Vol	: 000	Spare 3	: 0000
	A2 Middle Aspirate Vol	: 000	Spare 4	: 0000
	A2 Middle Dilution Macro	:	Spare 5	: 0000
	A2 Wash/Rinse Macro	:		
45	A2 Cleaner Volume	: 000	ADF Name	: PT.ADF
	A2 Cleaner AirSlug	: 000		
	A2 Rinse Volume	: 000		

-31-

TABLE 3 - adf Parameters for Plasminogen

5	A1 Run Volume	: 50	A3 Reagent Volume	: 050
	A1 Pump Velocity	: 1500	A3 Reagent Airslug	: 005
	A1 Sample Location	: 001	A3 Pump Velocity	: 1250
	A1 Sampling Macro	: SFSTASP2	A3 Reagent Location	: 004
	A1 Dilution Count	: 000	A3 Fetch Macro	: FETCH1
10	A1 Dilution Mix (1:x)	: 000	A3 Deliver Macro	: DELREAGENT
	A1 Dilution Sample	: 010	A3 Wash/Rinse Macro	: WASH
	A1 Dilution Primer	: 010	A3 Cleaner Volume	: 010
	A1 Dilution Aspirate	: 000	A3 Cleaner AirSlug	: 045
	A1 Dilution Macro	:	A3 Rinse Volume	: 800
15	A1 Non-Serial Dilution Count	: 000		
	A1 Wash/Rinse Macro	: RINSEP	A4 Reagent Volume	: 050
20	A1 Cleaner Volume	: 000	A4 Reagent AirSlug	: 040
	A1 Cleaner AirSlug	: 000	A4 Pump Velocity	: 1500
	A1 Rinse Volume	: 800	A4 Reagent Location	: 004
			A4 Fetch Macro	: FETCH1
	A2 Dilution Volume	: 040	A4 Deliver Macro	: DELOPTICS
25	A2 Primer Volume	: 140	A4 Wash/Rinse Macro	: WASH
	A2 Aspirate Volume	: 155	A4 Cleaner Volume	: 010
	A2 Dilution AirSlug	: 000	A4 Cleaner AirSlug	: 080
	A2 Pump Velocity	: 1600	A4 Rinse Volume	: 800
	A2 Buffer Location	: 003	Assay Blank time	: 005
30	A2 Dilution Macro	: BFSTRA	Assay Maximum Time	: 060
	A2 Dilution Count	: 002	Normalization Value	: 3000
	A2 Dilution Concentrat	: 005	Replicate Count	: 000
	A2 Dilution Mix (1:x)	: 020	Wavelength Count	: 003
	A2 Non-Serial Dilution Count	: 001	2, 3, 34	
35				
			Dltn Recalc Override:	: 0001
	A2 Throw Away Volume	: 100	Spare 2	: 0000
40	A2 Middle Dilution	: 010	Spare 3	: 0000
	A2 Middle Primer Vol	: 040	Spare 4	: 0000
	A2 Middle Aspirate Vol	: 050	Spare 5	: 0000
	A2 Middle Dilution Macro	: BMIDASP		
	A2 Wash/Rinse Macro	: RINSEC		
45	A2 Cleaner Volume	: 000		
	A2 Cleaner AirSlug	: 000		
	A2 Rinse Volume	: 800		

-32-

The universal testing profile is an extremely important part of this invention. All known coagulation analyzers, semi-automated and automated, perform on the basis that each test requires a unique profile. For example, only Prothrombin (PT) or only APTT assays are to be run at any given time as a batch, and therefore such machines are programmed to run the same way for each sample. They are incapable of doing a prothrombin time test on one sample and an APTT on the next, as the temperature vs. time parameters of each test are different. Some analyzers can perform multiple batch analysis simultaneously, but do not use the same profile. One way of doing so is being having unique pathways for each batch mode. The universal thrombosis and hemostasis temperature profile (temperature vs. time) is a method that allows all coagulation assays to be run through the same linear transport system using the same timing sequence, on the analyzer, to produce the necessary profile, with variables being the probe delivery temperatures and volumes, which are functions of parameters established by the adf.

The universal profile represents a balance between the different thermal requirements for each assay. This allows coagulation assays to be performed in a continuous, fully automated format.

There are nine critical requirements of the preferred universal thrombosis and hemostasis profile:

-33-

1. The temperature of the sample dispensed into the cuvette is preferably between about 4°C and about 25°C.

2. The sample must remain in a temperature range of from about 4°C to about 25°C until the heating sequence begins.

3. The time required to warm the sample temperature from the pre-ramp temperature range to the post-ramp temperature range is 80 ± 10 seconds.

4. The temperature of the sample at the end of the ramp must be $33^{\circ}\text{C} \pm 1^{\circ}\text{C}$.

5. If the test is an APTT, the activation reagent is added immediately at the end of the ramp (Arm 3).

6. The temperature of the reagent delivered at R1 is $40^{\circ}\text{C} \pm 1^{\circ}\text{C}$, raising the reaction temperature to 37°C .

7. If the test is a PT, the sample must reach $37^{\circ}\text{C} \pm 1^{\circ}\text{C}$ in 120 ± 10 seconds after the 80 second ramp segment (Arm 4).

8. The temperature of the reagent delivered at R2 is $37^{\circ}\text{C} \pm 1^{\circ}\text{C}$.

9. The temperature of the mixture must remain at $37^{\circ}\text{C} \pm 1^{\circ}\text{C}$ for at least 360 seconds after R2.

These temperature and time controls occur due to the interaction of the heated probes that aspirate and dispense liquids, which are described in more detail in US 5,178,019 to Keiter, and the portion of the sample

-34-

handling system, the heating and cooling track, as described in USSN 07/833,950.

5 Flexibility in the adf allows for minor changes in temperature profiles that allow for the total optimization of each assay. Diagrams of the profile and optimization ranges for the PT and APTT assays are attached (see Figure 2).

10 Another aspect of the sample preparation segment of the automatic coagulation analyzer is a means to automatically dilute samples. The analyzer performs a wide range of serial and nonserial dilutions for a large set of assays in a real time format. The adf for each complex method (methods requiring dilutions) defines the dilution: serial and non-serial, which buffers to use, 15 how to dilute concentrated buffers and which arm to perform the dilution on (arm 1 or 2). Successful dilutions are a function of fluidic movement, probe design and robotic design. In addition, the analyzer, with its built-in quality control and quality assurance 20 programming, ensures the accuracy of the dilutions. Figure 3 shows the relative absorbance rates of a dye sample, serially diluted. A least squares regression line is also shown, and its goodness-of-fit measure r^2 .

25 Finally, the analyzer provides a means for monitoring levels of the reagents in their containers and of the samples in their sample tubes or holding devices. This is another necessary function for a fully

-35-

automated analyzer, as an assay cannot be performed without the proper amount of reagents. In the present analyzer, a reagent chamber holds a large number of reagent containers, at a temperature of about 7°C, and some reagents may be automatically mixed to maintain a homogeneous suspension. If necessary, the reagent is heated in the probe before dispensing. Fluid level sensing is used to control the height of a reagent probe relative to the level of a reagent in its container.

IV. Optical Inspection

Once the reagents are added to the test sample, the reaction, if any, is read through spectrophotometric means. The optical inspection segment of the analyzer consists of a means for multiple wavelength analysis; a means to continuously normalize the fluctuations in light levels associated with sample to sample variability; and a means for using a broad spectrum of wavelengths in order to read the results of a variety of test reactions at the appropriate wavelength for that test.

As stated above, a preferred format of these functions are well-described in US 5,002,392 and USSN 07/869,579.

The quality control programming insures proper wavelength selection by monitoring the signal noise to ratio for each sample as defined in the adf. If the

-36-

signal to noise threshold is exceeded then another wavelength is used. If all wavelengths are unacceptable then an error flag is provided to the user.

5 The quality assurance programming assures that the true wavelength is being evaluated by incorporating a piece of spectral glass with known absorbance characteristics. The peaks are measured by the analyzer and compared to the known values. Furthermore, a liquid crystal clot simulator has been incorporated into the optics module that when properly stimulated creates a
10 signal that is similar to a clot. The output is inspected to insure the integrity of the optics unit as well as the integrity of the analysis algorithms.

15 V. Signal Processing

 The signal processing segment of the analyzer is the segment that reports the results of the assays. The analyzer has the ability to determine kinetic endpoints; to do multirule analysis of the final test results; to
20 perform complex processing that determines endpoints other than clot formation; and provides an on-line database against which each test result can be compared.

 An endpoint algorithm library is required to facilitate the analysis of the different types of
25 assays. The major categories of endpoint analysis are linear rates, logarithmic rates, relative magnitudes and kinetic endpoints based on the biological

-37-

characteristics of multianalyte mixtures (i.e., clot formation).

For example, the standard way of determining a PT or APTT clotting time is to take a sample, add the appropriate reagents and visually or spectrophotometrically determine when a clot has formed. When visually inspecting a sample for clot formation, the sample will turn more turbid after a clot has formed. Semi-automated analyzers set an endpoint at an arbitrary level of light reduction that is somewhat equitable to the visual method. However, this method is susceptible to error due to the presence of mechanical, optical, electrical and biological artifacts. Furthermore, as the instrument "ages", decreases in light transmission can result in a shift in the endpoint times.

Visual clot formulation occurs when the specimen mixture turns turbid. This can be physiologically associated with the initial conversion of fibrinogen to fibrin. (See, E. Ludvigh, "Perception of Contour," Bureau of Medicine and Surgery, Proj. No. NM001 075.01.04, Aug. 17, 1953.) The maximum rate of acceleration, the time of the peak of the second derivative, is indicative of the initial fibrinogen, fibrin conversion and directly correlates to a visual method (see Figure 5). Because the time is computed on a data stream that is independent of arbitrary

-38-

thresholds the usual artifacts associated with the instrument and biologics are negated resulting in more accurate and precise results. The same approach of analyzing characteristics of the signal stream for unique parameters is applied to the calculation of rate and magnitude for chromogenic, immunologic and quantitative fibrinogen assays.

For complex assays, kinetic endpoint results, such as clot times and reaction rates, additional processing is required. In these assays, the desired reported value of a sample is a function of some reference curve, which relates a quantity of a known analyte to reported endpoint values. Typically, a series of endpoint-based tests are performed on a series of concentrations from dilutions of a reference material. The paired data sets of recovered and reported values are then used to construct the reference curve.

The reference curve represents a function which is a model built using the sample data. (See, "Computer Evaluation of Reference Curves for the Estimation of Extrinsic Coagulation Factors," Frank et al., Comput Biol Med, Jan 1978). Traditionally, these functions have been assumed to be of a form similar to

$$f(\text{recovered value}) = a_1 g(\text{reported value}) + a_0$$

-39-

where $f()$, $g()$ are typically $\log_{10}()$. This function is particularly easy to represent graphically by hand, and numerically the coefficients can be recovered by simple linear regression using the formulas,

$$\text{slope} = \frac{n\sum xy - (\sum x)(\sum y)}{n\sum x^2 - (\sum x)^2}$$

$$\text{intercept} = \bar{Y} - \text{slope } \bar{X}$$

This type of function, while seemingly accurate, especially when calculated graphically by hand, is not representative of the true biological processes and leads to errors because points deviating from a straight line on a log-log reference curve are thought to deviate by random error and are neglected.

These simple functions restrict the degrees of freedom necessary to accurate model coagulation assays, which are more complex than simple chemical determinations based on known formulas. There are agents present in addition to the analyte of interest that complicate the cause-effect relationship.

The methods available in this invention allow for more flexibility in designing a model of the reference function which relates the desired reported results with recovered values. These functions provide a more

-40-

accurate representation of the shape of the reference curve for each assay, accommodating unknown extraneous agents, which leads to more accurate and precise results; also provide robustness in the presence of small errors in the data; gives accurate representation of all sample data, without neglecting points; and providing for an increased range of reference recovery due to incorporation of all dilutions, including those that were once ignored due to deviation from the straight line.

Three methods that are generally used to create models from experimental data are: (1) Gauss Jordan and (2) Singular Value Decomposition (SVD) for linear systems, and (3) Levenberg-Marquardt Method for non-linear systems. Gauss-Jordan is generally considered a simpler, but less accurate method for solving linear systems. Singular-Value is more costly in terms of number of operations, but it has the advantages of being more accurate, and is robust in the presence of singularities, where Gauss-Jordan cannot function. These singularities are approached when there are two solutions very close together, which is not uncommon. The error creeps into Gauss-Jordan when two very large numbers cancel each other when there is a very small pivot (i.e., close to singular). The accuracy of SVD and Levenberg-Marquardt methods are comparable.

-41-

The general form of a linear (in its coefficients) data model is

$$y(x) = \sum_{k=1}^M a_k X_k(x).$$

5

The merit function typically used to determine the best set of parameters a_k is

$$\chi^2 = \sum_{i=1}^N \left[\frac{y_i - \sum_{k=1}^M a_k X_k(x_i)}{\sigma_i} \right]^2.$$

10

The minimum of this function is found where the derivative of χ^2 with respect to all M parameters $a_k=0$, which leads to what are known as the normal equations, or a linear system

15

$$\sum_{j=1}^M \left[\sum_{i=1}^N \frac{X_j(x_i) X_k(x_i)}{\sigma_i^2} \right] a_j = \left[\sum_{i=1}^N \frac{y_i X_k(x_i)}{\sigma_i^2} \right].$$

20

In order to provide flexibility in determining the optimum reference function for each assay, several components were made available in the complex data analysis module:

- A variety of data transformations, i.e.,
log10, 1/, etc.;
- switching the x and y variables;

25

-42-

- Polynomials of any order; and
- Piecewise fitting, including overlapping.

The general form of the functions is

$$f(y) = c_0 + c_1 f(x) + c_2 f(x)^2 \dots c_n f(x)^n$$

5 where

$$f(x) = x, \frac{1}{x}, \frac{1}{f(x)}, \log(x) \dots$$

The "piecewise" form is

$$f(y) = [f_1(x)]_{x=a}^{x=b}, [f_2(x)]_{x=b}^{x=c}, \dots [f_n(x)]_{x=g}^{x=h}$$

10 where each "subfunction" can be a different type base on any combination of the sample data. Having the ability to select from the above options, an optimum reference function was selected for each complex assay. These optimized reference functions improve both the accuracy and precision of the assays. Each method was tested to determine if samples with known reported values were reported accurately, if diluted samples resulted in reported values at the expected levels, and if the sample data were fit well (R^2).

15

20

VI. Quality Assurance

An important part of the quality control package is the use of statistical quality control rules applied to test data. This is very similar to the tests originally utilized for clinical chemistry quality control programs, known as the Westgard multirule systems but

25


-43-

that have been applied to coagulation assays (See, Westgard, J., Wiebe, D., "Cholesterol Operational Process Specifications for Assuring the Quality Required by CLIA Proficiency Testing," Clinical Chemistry, Vol. 37, No. 11, pp. 1938-1944, 1991; and Westgard, J., Peterson, P., Wiebe, D., "Laboratory Process Specifications for Assuring Quality in the U.S. National Cholesterol Education Program," Clinical Chemistry, Vol. 37, No. 5, pp 656-661, 1991). This is available for use in two portions of the analyzer, the system quality control program and the on-line test quality control.

The system quality control defaults to a new control run mode when the allotted time designated for control run frequency is reached. The system pauses for the control run, which can only be overridden when an emergency sample is requested. Once the controls are assayed, the statistical quality control rule chosen is activated to interpret the results of the controls. If data passes the rules, quality control results are printed on a hard copy while being simultaneously saved to the on-board computer. If data violates any of the rules, it is flagged through a hard copy and the analyzer's monitor. The user has an option to either repeat the control, troubleshoot the cause of the flag or accept flagged control values.

A preferred variation of statistical rule data structure is shown in the following Table 4.

Table 4. Statistical Rules Data Structure



20 The purpose of the statistical quality control rules is to take an array of raw data (which may include data from several different controls or levels) and apply a set of tests to it. The set of tests, if chosen properly can have a very low false rejection rate coupled with a very high probability of rejection of bad results. Before the tests are applied to the data, they are converted to z-scores (normalized) using the level

25

-45-

data, allowing different controls to be analyzed together. There can be any number of tests in a statistical rule, and a pair of results is returned for each individual test: one based on clinically significant ranges and one based on statistically significant ranges. Any number of raw data points may be used, as the rules assume that all of the data is to be examined. If GROUP window_flag is selected, the data will be divided into n/N groups. If SLIDING window_flag is chosen, the data will be arranged into (n-N) groups, each group starting at one point past the previous. One test result is returned for all groups - if one group fails, FAILED is the result returned; if all groups pass, PASSED is the result returned. In the case of GROUP and n not divisible by N, the last remaining points are ignored. All data selection is done external to multirules. If there is a "missing point" or if "historical data" is required, it is taken care of before the function is called, in the database query, or its equivalent. In the unexpected case of a set of rules having N's without a common denominator, a group of statistical rules can be used. This can be accomplished by building an object with multiple member statistical rules that returns the result of the cumulative result of its members.

The operation of the sample handling system will now be described in the context of the following

-46-

specific implementations of the invention, it being understood that the invention is not limited to these particular implementations.

5 Example I. Mechanical Operation of the Analyzer.

 An example of the operation of a preferred analyzer is the following. Operation of the sample handling system according to the invention is centered on a linear track along which cuvettes are advanced from station to station by a lead screw. The basic timing and sequencing of the system is based on advancing the cuvettes along the linear track a distance equal to the distance between successive reaction wells.

10

 Initially, an operator loads cuvettes into the instrument by placing a cassette of cuvettes into a cassette frame. Each cassette holds, for example, 120 cuvettes. The cuvettes are automatically moved from the cassette onto a loading ramp, thus allowing for uninterrupted flow of cuvettes while a cassette is being added to the system. Cuvettes are loaded from the ramp onto the linear track as scheduled, by an arm where they engage the lead screw. Each cuvette preferably has four 1/4 inch reaction wells. The lead screw is activated every twenty seconds to move the cuvettes in 0.25 inch increments in 0.2 seconds. The instrument controller monitors each cuvette by the timing associated with the lead screw. The lead screw advances the cuvettes to the

15

20

25

-47-

first station, i.e., the sample insertion station, where a sample is delivered to a reaction well aligned with the sample probe. After delivering the sample, the probe is automatically washed. Two minutes and 40
5 seconds later, the reaction well of the cuvette arrives at the first reagent delivery probe where diluent or a reagent is added, depending on the test being carried out. The probe is automatically washed after each delivery with a washing agent that is correct for
10 removing that particular reagent. The second reagent probe is located two minutes and forty seconds after the first reagent probe, where an activator can be added. Three minutes and forty seconds later the loaded reaction well of the cuvette reaches the third reagent
15 probe where a reagent is added and the reaction monitoring begins. The reaction is monitored electro-optically by an optical monitoring system, which measures changes in the optical transmission of the reaction volume as the clot forms or as the chromometric
20 reaction proceeds. As the cuvette is moved along the track, the optical monitoring continues for twenty consecutive stations, that is, for 300 seconds. Following the optical monitoring station the cuvette leaves the track and is sent to a waste container.

25 Patient plasma samples are stored in a refrigerated housing in the original evacuated blood collection tubes used to obtain the patient's sample which has been

-48-

previously spun down to obtain the plasma and bar coded for patient identification and test protocol to be performed. The evacuated sample collection tubes are placed in the holders of shuttles and advanced by the shuttle drive mechanism to the bar code reader. The evacuated sample collection tubes can be arranged in any order since the bar code on each sample collection tube allows the instrument to automatically correlate a patient with a given sample. The bar code read by bar code reader also programs the instrument controller for determining the amount of sample to be aspirated by the sample probe, the number of reaction wells to be filled with the sample, and the amounts and types of reagents/buffers/additives/activators to be injected into the respective reaction wells by multiple reagent probes. Subsequent to the programming station, a sample collection tube is advanced to a piercer where the piercing tube is caused to pierce the septum of the evacuated sample tube to allow the sample probe to be lowered into the sample collection tube to aspirate a programmed amount of sample. The sample probe is next removed from the evacuated sample collection tube and horizontally moved over a reaction well positioned at the sample insertion station and lowered into the reaction well where a programmed amount of sample is expelled into the reaction well. The evacuated sample collection tubes can be removed from the refrigerated

-49-

housing at any time after sample aspiration is complete; however, because the samples are maintained at lowered temperatures, they can be retained for further testing without having to be immediately removed from its shuttle. The reagent chamber stores various controls, diluents, activators and reagents. In one implementation of the system up to twenty-two containers of these materials are stored in the reagent chamber. All containers are held to a temperature of about 9 - 15° C and the reagents are heated, if necessary, in the reagent probe as they are being dispensed.

Pumping in all cases is performed with positive displacement syringe pumps operatively connected with respective ones of the probe. No manipulation of pump tubing is required as is the case with peristaltic pumps. A reagent is dispensed into a reaction well in a manner that promotes mixing with the sample and other contents of the reaction well. The reagent temperature and volume are controlled by the instrument controller.

Desirably, fluid level sensing is utilized to control the height of a reagent probe relative to the level of a reagent in its container and relative to the contents of a reaction well. This permits bringing the outside of a probe into contact with a minimum quantity of reagent. This, in turn, reduces the possibility for carry-over. Additionally, level sensing is used to control the height of a probe above the fluid level

-50-

while dispensing in order to minimize carry-over and to maximize mixing.

At the same time that all of the above mechanical and programmed functions are occurring, various quality assurance/quality control checks are being automatically performed. Also, data calculations are being automatically performed in order to produce and deliver a final result of the parameter being assayed for. This is shown in the following example.

Example II. Example for Factor VIII on an Automated Analyzer

A Factor VIII assay was conducted to determine the relative quantity of the intrinsic pathway cofactor VIII (FVIII). FVIII concentration is critical in clot formation and deficiencies of it are symptomatic of a hemophiliac condition. It is important to be able to accurately quantitative the FVIII concentration in patient specimens. The invention addresses all aspects of properly performing the complex FVIII Assay.

A FVIII Assay consists of three types of sample evaluations:

1. Reference materials to normalize the reagent system.
2. Control materials to assure the quality of the reference curve.

-51-

3. Patient samples to aid in the diagnosis and treatment of the patient.

Specimen handling and dilutions (Arm 1)

The Factor VIII assay requires the dilution of sample (be it reference, control or patient) serially from a 1:5 to 1:1280. Each type of material requires a different set of dilutions that can be prescribed at time of sampling. The sample was diluted with Imidazole buffer that was contained in the ARM1 reservoir. The Factor VIII reference curve was and is typically prepared as follows:

1. 90uL of Imidazole was loaded into the syringe from the reservoir from arm 1.
2. The arm moved to the appropriate sample reservoir and aspirated 10uL plasma.
3. The total 100uL was delivered to the cuvette.
4. The probe then loaded 50uL of Imidazole from the reservoir for arm 1.
5. 50 uL of the 100uL was aspirated from the cuvette.
6. The track was incremented forward and the 50uL aspirated from the previous well along with the 50uL of Imidazole were delivered into the new well.
7. Steps 4 through 7 were repeated for each additional serial dilution required.

-52-

The end result was a FVIII reference curve with seven serial dilutions from a starting dilution of 1:10. The patient and control samples were diluted in the same fashion. Three serial dilutions were performed on a patient sample starting at 1:20, and 2 dilutions on the control material starting at 1:20. The system allows modification of the initial dilution ratio and the number of serial dilutions on a per patient basis.

Quality Checks: The ability to properly perform dilutions was verified using the dye verification process described in the sample preparation detailed description (See Figure 3). If the plasma volume in the primary reservoirs is insufficient, a level sense error is generated. If insufficient volume for the Imidazole reservoir is detected, an error message is given.

Reagent Addition and Incubation

After the appropriate volume of plasma and buffer has been added to the test well, then the appropriate reagent must be added at the appropriate times to prepare the well for optical inspection.

Addition of factor deficient plasma (Arm 2):

The FVIII assay required the addition of 50uL of Factor deficient material 2 minutes and 40 seconds after arm 1. The well was still maintained at ambient temperature.

-53-

Addition of Activator (Arm 3):

The FVIII assay is an APTT based assay (test of the intrinsic pathway) and required the addition of an activator material at arm 3 approximately 2 minutes and 40 seconds after the addition of the factor deficient material. During the 2 minutes and 40 seconds the test well is warmed from ambient temperature to about 33°C, then 50uL of activator was added at 39°C raising the temperature in the test well to 37°C. The activator was stored on the reagent tray at 8°C and mixed automatically to maintain a homogenous suspension.

Addition of Calcium Chloride (Arm 4):

The sample was then incubated for 3 minutes 40 seconds at 37°C. The incubation/activation time is critical for clot based test measuring parameters of the intrinsic pathway. At the end of activation, 50uL of 0.25M calcium chloride was added at 37°C, starting the reaction.

Quality Checks: The correct volumes of reagents delivered was assured by the dye tracking system. The quality of the reagents was assured by using the multirule analysis quality control program defined earlier. The thermal profile was monitored by querying temperature sensors as a test well goes over them. If the temperature is determined to be out of range then an error message is reported to the user.

-54-

Optical Inspection

The test well was optically inspected for up to 300 seconds. During this inspection process the test well was exposed to fifteen different optical windows for 20 seconds each. A normalization process was required at the first optical windows that normalizes all other windows to the first. Additionally, the normalization process also removes the differences in light levels associated with variability due to the unique turbidity of each plasma. The data was collected for a unique set of assay specific wavelengths and stored in a data file. The data file also contained the data set required to determine quantities of preanalytical variables and dye concentrations for volume verification.

Quality Checks: There are quality checks for wavelength verification, optical integrity (Liquid Crystal Clot Simulator), and an acceptable signal to noise ratio as an indication of proper normalization.

Data Analysis

Endpoint determinations and calibrations:

All endpoints for the test well data files were computed using the peak of the second derivative described above. The endpoints were standardized using a unique calibration scheme. Systematic bias associated with reagent lot to lot variability and instrument to instrument variability was minimized by calibration of

-55-

the system using labeled plasma calibrators. For more current coagulation systems, systematic error in the measurement of clotting times is due to instrument thermal and fluidic variation as well as in variation in reagent lot to lot sensitivity. Therefore, reference and therapeutic intervals are specific for each instrument and reagent lot and are routinely redetermined. The analyzer's calibration procedure normalized instrument mechanical variables and reagent inter-lot sensitivity, providing uniform APTT clotting times suitable for direct reporting or for use in standardization methods. The analyzer's APTT assays (including FVIII) were calibrated by replicate analysis of VeriCal Calibration Plasmas™ (Organon Teknika) that have assigned clotting times. Observed values were regressed versus assigned values and the resulting regression coefficients were used to normalize the instrument/reagent system.

Reference Curve Generation

Reference curves were constructed by taking the dilution and known concentration of the reference material and regressing it with the obtained endpoint for each test well. The type of regression and analysis tool used dictates the quality of the reference curve and ultimately the quality of the patient result. The traditional method of constructing a Factor VIII

-56-

reference curve, log-log transformation, fit to a first order polynomial is not representative of the true biological processes. The curve is better represented by the technique used for this invention. The improvements are most prevalent in the 50 to 100% range and 1 to 10% range, both ranges being clinically significant. The reference curve was constructed by plotting the % activity for the seven dilutions as the independent variable (x), and clotting time as the dependent variable (y). The function is piecewise and discontinuous and composed of two linear sub-curves fit to overlapping sets of data. The first sub-curve uses the first four dilutions and fits a second order polynomial to untransformed data. The second sub-curve fits a second order polynomial to log10 (clot times) and log10 (%activity) to all of the dilutions after the first one. A "cutoff", which determines which sub-curve is used to recover % activity, is established based on the clot time corresponding to the fourth dilution value recovered from the curve. The curve accurately represents the shape of the expected values, and remains robust in the presence of minor variance in the data. Figure 4 shows a comparison between the traditional Factor VIII reference curve and the automatic analysis Factor VIII assay reference curve.

-57-

The patient samples were evaluated with respect to a stored or newly generated reference curve and the reported value was corrected for dilution automatically.

Quality Control Checks: Measures of Goodness of fit for the calibration process and the reference curve structure used were defined earlier. The control values were monitored and subjected to the quality control multirule analysis procedures. The slope of the sample dilutions when compared with the controls or reference curve are determined to assess for the presence of Factor VIII inhibitors such as the Bethesda inhibitor.

It will be understood that the above description of the present invention is susceptible to various modifications, changes and adaptations, and the same are intended to be comprehended within the meaning and range of equivalents of the appended claims.

-58-

WE CLAIM:

1. A method for performing qualitative and quantitative coagulation, chromogenic and immunological assays for hemostasis and thrombosis parameters on each of a multiplicity of samples of plasma, serum or whole blood, wherein each sample is selected for assay on a random access basis, comprising:

a) providing a programming input means for identifying each of a multiplicity of samples, selecting a sample and scheduling one or more of hemostasis and thrombosis-related assays to be performed on the sample;

b) providing a specimen handling means for automatically transferring an aliquot of the sample from a holding device to a test well in a cuvette;

c) providing a sample preparation means for automatically selecting and adding reagents needed for a scheduled assay to measure hemostasis or thrombosis parameters to the sample in the test well in specific quantities at specified times and temperatures, thereby accommodating a single, universal temperature profile that is the same for all hemostasis and thrombosis assays, to obtain a reaction, wherein the selection, order and timing of the reagents added is in a random access format, thereby eliminating the need for batch analysis;

-59-

d) providing a detecting means for detecting the reaction in the well and measuring the data from the reaction;

e) providing a processing means for mathematically processing the measured data to evaluate a change in or magnitude of the measured data from the reaction in the well; and

f) providing a reporting means to report results of processing the measured data by the processing means;

thereby automatically performing hemostasis and thrombosis-related assays and determining and reporting results on hemostasis and thrombosis parameters in the sample.

2. The method according to claim 1, wherein additionally is included providing a means for independently defining a test protocol for each assay.

3. The method according to claim 2, wherein the test protocol includes mechanical instructions, optical instructions, data analysis and quality assurance parameters.

4. The method according to claim 1, wherein additionally is included providing a means for automatically diluting the transferred sample.

-60-

5. The method according to claim 1, wherein the method for controlling the addition of reagents at a specified time and temperature to accommodate a universal thermal profile comprises:

5 a) providing a means for independently controlling a cooling unit and maintaining the sample initially within a low temperature range having a predetermined maximum temperature;

10 b) providing a means for independently controlling a heating unit that maintains the sample in an optically monitored section in the detecting means within a predetermined measuring temperature range that is higher than the initial temperature range;

15 c) providing a means for transitioning the temperature of the sample from the initial range to the measuring temperature;

d) providing a means for reducing the effect of ambient temperature; and

20 e) providing a means for delivering reagents to the test well at a specified temperature.

6. The method according to claim 1, wherein following each use of the sample preparation means to dispense a sample or reagent into a well, the sample preparation means is washed by a wash liquid.

25

-61-

7. The method according to claim 6, wherein the wash liquid is selected from a group consisting of water, wash solution and bleach solution.

5 8. The method according to claim 1, wherein additionally is provided a computational means for evaluating data obtained from each assay by

 a) calculating the a second derivative of a process signal and determining the peak thereof, which is an
10 indication of maximum acceleration of clot formation; or

 b) calculating a magnitude of change of a process signal; or

 c) calculating a rate of change of a parameter, whereby a first derivative of the parameter is
15 determined; or

 d) a combination of the calculations of a) - c) above.

 9. The method according to claim 1, wherein the
20 data is transformed by normalization and calibration to standardized material by a numerical construction of a system model using known reference material, specific for each assay.

25 10. The method according to claim 9, further comprising a system model developed from a function with a linear or nonlinear relationship between recovered and

-62-

reported values, the function created by fitting to a set of sample data.

5 11. The method according to claim 1, comprising
providing a quality assurance means for monitoring and
evaluating the sample handling, sample preparation,
reaction detection and results reported by the reporting
means for the sample, wherein the quality assurance
comprises checks for sample integrity, reagent
10 integrity, mechanical suitability and optical quality.

15 12. The method according to claim 11, wherein the
check for sample integrity comprises detecting
preanalytical variables in the sample.

20 13. The method according to claim 11, wherein the
check for reagent integrity comprises evaluating control
material and applying statistical quality control rules
and a comparison of a current result to a earlier sample
result.

25 14. The method according to claim 11, wherein the
check for system suitability comprises measuring
electrical, volumetric and thermal output of critical
mechanical components.

-63-

15. The method according to claim 11, wherein the check for optical quality comprises monitoring an optical reference clot at an appropriate wavelength and monitoring the signal to noise ratio, thereby insuring the use of acceptable signals.

16. A method for providing a suitable thermal environment for performing hemostasis and thrombosis assays on a test sample, comprising providing a single universal temperature profile that is the same for all hemostasis and thrombosis assays.

17. The method according to claim 16, wherein said universal thermal profile comprises

a) dispensing the sample into a test well at a temperature range from about 4° C to about 25° C and maintaining the sample temperature in that range;

b) warming the sample within 80 ± 10 seconds to $33^\circ \text{C} \pm 1^\circ \text{C}$; and

c) immediately adding an activation reagent at a temperature of $40^\circ \text{C} \pm 1^\circ \text{C}$ and raising the reaction temperature to 37°C ;

thereby providing a universal thermal environment in which an Activated Partial Thromboplastin Time assay can be performed.

-64-

18. The method according to claim 16, wherein said universal thermal profile comprises

a) dispensing the sample into the test well at a temperature range from about 4° C to about 25° C and maintaining the sample temperature in that range;

b) warming the sample within 80 ± 10 seconds to $33^\circ \text{C} \pm 1^\circ \text{C}$; and

c) increasing the sample temperature to $37^\circ \text{C} \pm 1^\circ \text{C}$ within 110 seconds to about 130 seconds after

b), delivering a reagent at a temperature of $37^\circ \text{C} \pm 1^\circ \text{C}$, and maintaining the temperature of the mixed reagent and sample at $37^\circ \text{C} \pm 1^\circ \text{C}$ for a minimum of 360 seconds,

thereby providing a universal thermal environment in which a Prothrombin Time assay can be performed.

19. An instrument for automatically performing assays for hemostasis and thrombosis parameters on each of a multiplicity of samples of plasma, serum or whole blood, whereby each sample is selected for assay on a random access basis comprising:

a) a programming input means for identifying each of a multiplicity of samples, selecting a sample and scheduling one or more hemostasis and thrombosis-related assays to be performed on the sample;

-65-

b) a specimen handling means for automatically transferring an aliquot of the sample from a holding device to a test well in a cuvette;

5 c) a sample preparation means for automatically adding reagents needed for a scheduled assay to measure hemostasis or thrombosis parameters to the sample in the test well at a specified time and temperature, accommodating a universal thermal profile, to obtain a reaction, wherein the order of the reagents added can be
10 in a random access format thereby eliminating the need for batch analysis;

d) a detecting means for detecting the reaction in the well and measuring the data from the reaction;

15 e) a processing means for mathematically processing the measured data to evaluate a change in or magnitude of the measured data from the reaction in the well; and

f) a reporting means to report results of processing the measured data by the processing means;

20 thereby automatically performing hemostasis and thrombosis-related assays and determining and reporting results on hemostasis and thrombosis parameters in the sample.

25 20. The instrument according to claim 19, wherein additionally is included a means for independently defining the test protocol for each assay.

-66-

21. The instrument according to claim 19, wherein the test protocol includes mechanical instructions, optical instructions, data analysis and quality assurance parameters.

5

22. The instrument according to claim 19, wherein additionally is included a means for automatically diluting the transferred sample.

10

23. The instrument according to claim 19, wherein the method for controlling the addition of reagents at a specified time and temperature to accommodate a universal thermal profile comprises

15

a) a means for independently controlling a cooling unit, maintaining the sample initially within a low temperature range having a predetermined maximum temperature;

20

b) a means for independently controlling a heating unit that maintains the sample in an optically monitored section within the detecting means, within a predetermined measuring temperature range that is higher than the initial temperature range;

25

c) a means for transitioning the sample from the initial range to the measuring temperature by the use of a temperature ramp;

d) a means for reducing the effect of ambient temperature; and

-67-

e) a means for delivering reagents to the test well at a specified temperature.

5 24. The instrument according to claim 19, wherein following each time the sample or reagent is dispensed into a well, the sample preparation means is washed by a wash liquid.

10 25. The instrument according to claim 24, wherein the wash liquid is selected from a group consisting of water, wash solution or bleach solutions.

15 26. The instrument according to claim 19, wherein additionally is provided a computational means for evaluating data obtained from each assay by

a) calculating a second derivative of a process signal and determining the peak thereof, which is an indication of maximum acceleration of clot formation; or

20 b) calculating a magnitude of change of a process signal; or

c) calculating a rate of change of a parameter, whereby a first derivative of the parameter is determined; or

25 d) a combination of the calculations of a) - c) above.

-68-

27. The instrument according to claim 19, wherein transformation of said parameter is accomplished by normalization and calibration to standardized material by a numerical construction of a system model using
5 known reference material, specific for each assay.

28. The instrument according to claim 27, further comprising a system model developed from a function with a linear relationship between recovered and reported
10 values, the function created by fitting to a set of sample data.

29. The instrument according to claim 19, wherein the quality assurance means comprises checks for sample
15 integrity, reagent integrity, mechanical suitability and optical quality.

30. The instrument according to claim 29, wherein the check for sample integrity comprises detecting
20 preanalytical variables in the sample.

31. The instrument according to claim 29, wherein the check for reagent integrity comprises evaluating control material and applying statistical quality
25 control rules and a comparison of a current result to a earlier sample result.

-69-

32. The instrument according to claim 29, wherein the check for system suitability comprises measuring electrical, volumetric and thermal output of critical mechanical components.

5

33. The instrument according to claim 29, wherein the check for optical quality comprises monitoring an optical reference clot at an appropriate wavelength inspection and monitoring the signal to noise ratio, thereby insuring the use of acceptable signals.

10

34. An instrument for providing a suitable thermal environment for performing hemostasis and thrombosis assays on a test sample, comprising providing a single universal temperature profile that is the same for all hemostasis and thrombosis assays.

15

35. The instrument according to claim 34, wherein said universal thermal profile comprises

20

a) dispensing the sample into a test well at a temperature range from about 4° C to about 25° C and maintaining the sample in the range;

b) warming the sample within 80 ± 10 seconds to $33^\circ \text{C} \pm 1^\circ \text{C}$; and

25

c) immediately adding an activation reagent at a temperature of $40^\circ \text{C} \pm 1^\circ \text{C}$ and raising the reaction temperature to 37°C ;

-70-

thereby providing a universal thermal environment in which an Activated Partial Thromboplastin Time assay can be performed.

5 36. The instrument according to claim 34, wherein said universal thermal profile comprises

a) dispensing the sample into a test well at a temperature range from about 4° C to about 25° C and maintaining the sample in the range;

10 b) warming the sample within 80 ± 10 seconds to $33^{\circ} \text{C} \pm 1^{\circ} \text{C}$; and


c) increasing the sample temperature to $37^{\circ} \text{C} \pm 1^{\circ} \text{C}$ within 110 seconds to about 130 seconds after reaching the 80 second segment, delivering a reagent at a temperature of $37^{\circ} \text{C} \pm 1^{\circ} \text{C}$, and maintaining the temperature of the mixed reagent and sample at $37^{\circ} \text{C} \pm 1^{\circ} \text{C}$ for a minimum of 360 seconds,

15 thereby providing a universal thermal environment in which a Prothrombin Time assay can be performed.

20

1/5

FIG. 1



2/5




FIG. 2

3/5

FIG. 3




FIG. 4





FIG.5



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/09226

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : G01N 1/28, 25/48, 33/48, 35/04

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 422/63, 64, 65, 67, 82.05, 105; 436/43, 47, 48, 49, 50, 54, 55, 164, 174, 179, 180, 807

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ----- Y	US, A, 4,483,927 (TAKEKAWA) 20 November 1984, see entire document.	16, 34 ----- 1-15, 17-33, 35, 36
X --- Y	US, A, 4,517,160 (GALLE ET AL.) 14 May 1985, col. 15, line 55 to col. 16, line 64.	16, 34 ----- 1-15, 17-33, 35, 36
X --- Y	US, A, 4,695,430 (COVILLE ET AL.) 22 September 1987, see the abstract.	16, 34 ----- 1-15, 17-33, 35, 36
Y	US, A, 4,971,913 (MANABE ET AL.) 20 November 1990, see the abstract.	1-36

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 17 OCTOBER 1994	Date of mailing of the international search report 22 DEC 1994
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer LONG LE Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/09226

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,958,295 (DAVIDSON ET AL.) 18 September 1990, see summary of the invention section.	1-36
Y	US, A, 5,100,622 (MIMURA ET AL.) 31 March 1992, see the abstract.	1-36

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/09226

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

422/63, 64, 65, 67, 82.05, 105; 436/43, 47, 48, 49, 50, 54, 164, 174, 180